What Is 5-Amino-1MQ?
<a href="/compounds/5-amino-1mq">5-Amino-1MQ</a> (5-amino-1-methylquinolinium) is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme increasingly linked to obesity, metabolic dysfunction, and fat cell expansion. Unlike most peptides in the research space, 5-Amino-1MQ is technically a small molecule rather than a peptide - but it is widely sourced through peptide vendors and used in similar research contexts.
NNMT is overexpressed in adipose (fat) tissue of obese individuals. By inhibiting this enzyme, 5-Amino-1MQ may reduce fat cell size, increase cellular energy expenditure, and improve metabolic markers. It is one of the few compounds in the research peptide space that targets fat metabolism through a completely novel mechanism - not through appetite suppression (like GLP-1 drugs) or growth hormone pathways.
How 5-Amino-1MQ Works: Mechanism of Action
NNMT Inhibition. NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3), consuming SAM (S-adenosylmethionine) in the process. When NNMT is overactive - as it is in obese individuals - it depletes the SAM pool and disrupts the methionine cycle. 5-Amino-1MQ blocks this enzyme, restoring normal methylation balance.
NAD+ Salvage Pathway. By inhibiting NNMT, more nicotinamide is available for the NAD+ salvage pathway. This increases intracellular <a href="/compounds/nad-plus">NAD+</a> levels, which drives mitochondrial function, energy metabolism, and sirtuin activity. Higher NAD+ is associated with improved metabolic health and longevity markers.
Fat Cell Regulation. NNMT inhibition has been shown to reduce adipocyte (fat cell) size and lipid accumulation in cell culture and animal studies. The mechanism involves increased energy expenditure at the cellular level - fat cells burn more energy rather than storing it.
Oral Bioavailability. Unlike most research peptides that require injection, 5-Amino-1MQ can be taken orally. This is a significant practical advantage, as the molecule survives gastric degradation.
Research Evidence
Obesity and Fat Metabolism The key foundational study (Neelakantan et al., 2018, Biochemical Pharmacology) demonstrated that NNMT inhibition with 5-Amino-1MQ reduced body weight and white adipose tissue mass in diet-induced obese mice. Treated mice showed a 30% reduction in fat mass without changes in food intake - meaning the fat loss was driven by metabolic changes, not appetite suppression.
Cellular Energy Expenditure In vitro studies show that NNMT inhibition increases oxygen consumption rate in adipocytes, indicating higher cellular energy expenditure. Fat cells treated with 5-Amino-1MQ effectively "burn hotter," consuming more energy at baseline.
Muscle Metabolism Emerging research suggests NNMT inhibition may also benefit skeletal muscle metabolism. NNMT is expressed in muscle tissue, and its inhibition may enhance muscle cell energy utilization and stem cell function - though this research is preliminary.
Metabolic Syndrome Markers Animal studies show improvements in multiple metabolic syndrome markers including fasting glucose, insulin sensitivity, and lipid profiles following NNMT inhibition.
5-Amino-1MQ vs. Other Fat Loss Compounds
5-Amino-1MQ vs. <a href="/compounds/semaglutide">Semaglutide</a>/<a href="/compounds/tirzepatide">Tirzepatide</a>. GLP-1 agonists work primarily through appetite suppression - they make you eat less. 5-Amino-1MQ does not affect appetite; it increases cellular energy expenditure so fat cells store less. Semaglutide and tirzepatide are FDA-approved and available through <a href="/clinics">telehealth clinics</a>; 5-Amino-1MQ is a research compound only.
5-Amino-1MQ vs. <a href="/compounds/aod-9604">AOD-9604</a>. AOD-9604 stimulates lipolysis (fat breakdown) through growth hormone receptor pathways. 5-Amino-1MQ works through NNMT inhibition, a completely different mechanism. AOD-9604 requires injection; 5-Amino-1MQ is oral.
5-Amino-1MQ vs. <a href="/compounds/mots-c">MOTS-c</a>. Both target metabolism but differently. MOTS-c activates AMPK (the exercise-mimetic pathway), while 5-Amino-1MQ inhibits NNMT to increase NAD+ and reduce fat cell activity. They work through non-overlapping mechanisms.
5-Amino-1MQ vs. <a href="/compounds/tesamorelin">Tesamorelin</a>. Tesamorelin is FDA-approved for HIV-associated lipodystrophy and works by stimulating growth hormone release. 5-Amino-1MQ targets fat metabolism directly at the enzymatic level. Tesamorelin is available by prescription; 5-Amino-1MQ is not.
Dosage Protocols in Research
Published research and community protocols typically reference:
- •Standard dose: 50-100 mg per day, taken orally
- •Common protocol: 50 mg twice daily (morning and afternoon)
- •Cycle length: 8-12 weeks
- •Administration: Oral capsules (no injection required)
The oral bioavailability of 5-Amino-1MQ is a significant advantage over injectable peptides. Most vendors sell it in capsule form.
Important: These doses reflect published research protocols and community reports. 5-Amino-1MQ is not FDA-approved for any indication. Consult a physician before considering any compound.
Where to Get 5-Amino-1MQ
5-Amino-1MQ is not currently FDA-approved and is not available through <a href="/clinics">peptide clinics</a>. It is classified as a research compound.
Research-grade 5-Amino-1MQ is available from several verified vendors, typically in capsule form. Pricing ranges from $50-90 for a 30-day supply at standard research doses. Check the <a href="/compounds/5-amino-1mq">5-Amino-1MQ compound page</a> for current vendor pricing comparison.
Key quality indicators when sourcing: - Third-party COA with identity and purity verification - HPLC analysis showing >98% purity - Vendors with transparent testing practices
See our <a href="/methodology">vendor scoring methodology</a> for evaluation criteria.
Side Effects and Safety
The safety profile of 5-Amino-1MQ in humans is not well established. Published research is primarily preclinical (cell culture and animal models). Reported side effects from community use include:
- •Mild gastrointestinal discomfort (most common, typically transient)
- •Occasional headache
- •Slight stimulant-like effect (likely related to increased cellular energy expenditure)
No serious adverse effects have been reported in published preclinical studies. However, the lack of human clinical trial data means the long-term safety profile is unknown.
Frequently Asked Questions
Is 5-Amino-1MQ a peptide? Technically no - it is a small molecule (a methylquinolinium compound). However, it is widely sold through peptide vendors and used in similar research contexts, which is why it appears in peptide databases and discussions.
Is 5-Amino-1MQ legal? Yes, 5-Amino-1MQ is legal to purchase for research purposes. It is not FDA-approved, not a controlled substance, and not available by prescription.
Can 5-Amino-1MQ be stacked with other compounds? Research has not formally evaluated combinations. The non-overlapping mechanism (NNMT inhibition) theoretically allows stacking with AMPK activators like <a href="/compounds/mots-c">MOTS-c</a> or GH secretagogues like <a href="/compounds/cjc-1295">CJC-1295</a>/<a href="/compounds/ipamorelin">Ipamorelin</a>, but this is speculative.
Does 5-Amino-1MQ suppress appetite? No. Unlike GLP-1 drugs, 5-Amino-1MQ does not affect appetite signaling. Any fat loss effects come from increased cellular energy expenditure, not reduced food intake.
How quickly does 5-Amino-1MQ work? Community reports suggest noticeable effects within 2-4 weeks. The animal study showing 30% fat mass reduction used a multi-week treatment protocol.
The Bottom Line
5-Amino-1MQ represents a genuinely novel approach to fat metabolism - targeting NNMT, an enzyme that most people have never heard of but that plays a significant role in obesity and metabolic dysfunction. The oral bioavailability is a practical advantage over injectable peptides.
However, the evidence base is almost entirely preclinical. There are no published human clinical trials. For those seeking proven, medically-supervised fat loss support, <a href="/compounds/semaglutide">semaglutide</a> and <a href="/compounds/tirzepatide">tirzepatide</a> are available through <a href="/clinics">telehealth peptide clinics</a> with extensive clinical data. 5-Amino-1MQ is a compound worth monitoring as research progresses, but it remains firmly in the experimental category.